Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19

Collin Herman, MD, Kirby Mayer, DPT, PhD, and Aarti Sarwal, MD

Neurology® 2020;95:77-84. doi:10.1212/WNL.0000000000009673

Abstract

Objective
The emergence of coronavirus disease 2019 (COVID-19) presents a challenge for neurologists caring for patients with preexisting neurologic conditions hospitalized for COVID-19 or for evaluation of patients who have neurologic complications during COVID-19 infection. We conducted a scoping review of the available literature on COVID-19 to assess the potential effect on neurologists in terms of prevalent comorbidities and incidence of new neurologic events in patients hospitalized with COVID-19.

Methods
We searched MEDLINE/PubMed, CINAHL (EBSCO), and Scopus databases for adult patients with preexisting neurologic disease who were diagnosed and hospitalized for COVID-19 or reported incidence of secondary neurologic events following diagnosis of COVID-19. Pooled descriptive statistics of clinical data and comorbidities were examined.

Results
Among screened articles, 322 of 4,014 (8.0%) of hospitalized patients diagnosed and treated for COVID-19 had a preexisting neurologic illness. Four retrospective studies demonstrated an increased risk of secondary neurologic complications in hospitalized patients with COVID-19 (incidence of 6%, 20%, and 36.4%, respectively). Inconsistent reporting and limited statistical analysis among these studies did not allow for assessment of comparative outcomes.

Conclusion
Emerging literature suggests a daunting clinical relationship between COVID-19 and neurologic illness. Neurologists need to be prepared to reorganize their consultative practices to serve the neurologic needs of patients during this pandemic.
The recent outbreak of SARS-CoV-2, designated “coronavirus disease 2019 (COVID-19)” by the World Health Organization (WHO), was officially declared a pandemic on March 11, 2020, and is expected to continue to spread globally.1,2 The disease spectrum ranges from largely asymptomatic infections with or without mild pneumonia to severe hypoxic respiratory failure with multiorgan dysfunction and/or shock.3 COVID-19 is spread through droplets with a highly variable incubation period (5–14 days) with a case fatality rate of 1.8%–3.4%.3 The highly transmissible nature, asymptomatic carriage, and the wide spectrum of illness make this disease challenging for health care systems. Neurologists face the daunting task of caring for patients with preexisting neurologic disease who contract the virus, infected individuals who present with neurologic emergencies requiring neurologic consultation, and patients with COVID-19 who develop secondary neurologic complications such as ischemic stroke, seizures, or encephalopathy during the course of their illness.4–6 This necessitates personal protective equipment (PPE) for emergent neurologic consultations as well as consideration of telehealth alternatives to reduce physical exposure for neurologists. A recent meta-analysis examining the prevalence of comorbidities in COVID-19 infections surprisingly reported no neurologic comorbidities and risk stratification scores that qualify patients for therapies like chloroquine have not yet incorporated neurologic disease together, potentially inflating the incidence.7,8 Hence, we conducted a scoping review of the available literature on COVID-19 to assess the prevalence of patients with preexisting neurologic disease and the incidence of neurologic complications following COVID-19 diagnosis.

Methods

The authorship team designed a primary literature search to understand the incidence of patients with preexisting neurologic disease who were diagnosed with and hospitalized for COVID-19 or had reported incidence of secondary neurologic events following diagnosis of COVID-19.

Eligibility criteria

Research studies were selected for inclusion if they met the following criteria: (1) adult patients (aged ≥18 years); (2) diagnosed and received inpatient treatment for COVID-19; and (3) reported data on preexisting neurologic comorbidities or neurologic events occurring during the course of the illness. Additional articles were included through a gray search via Google search engine and manual review of references listed articles to find relevant articles. Studies were not restricted according to design and had to be available in the English language. Because of the rapidly evolving state of the COVID-19 pandemic, non–peer-reviewed articles available via pre-acceptance open access were included. We did not find any pediatric literature relevant to this review.

Results

Preexisting neurologic disease and COVID-19 diagnosis

Articles were screened by title and abstract. Twenty-two studies met the inclusion criteria (figure). Twenty retrospective studies,6,10–28 1 prospective observational trial,29 and 1 randomized controlled trial30 were included. Twenty studies were conducted in China, 1 in Italy, and 1 in France. In total, 4,014 patients were included, with a mean age of 55.6 ± 8.4 years and 57% male predominance. The pooled percentage for having a preexisting neurologic disease was 8.0% (n = 322/4,014, range of 0%–40% for individual studies; table 2). The presence of preexisting neurologic disease was frequently not specified and grouped only as cerebrovascular disease, nervous system disease, or history of prior stroke. In addition, 5 studies grouped cerebrovascular disease and cardiovascular disease together, potentially inflating the incidence.17,19–21

We found headache to be a commonly reported symptom at presentation as it was mentioned in 22 articles. However, headache was not reported as a comorbidity and hence not included. Other neurologic comorbidities rarely mentioned in screened articles included dementia and Parkinson disease (table 1). We did not find a mention of anosmia in any searched scientific literature. We attempted but were unable to assess comparative outcomes from COVID-19 in patients with preexisting neurologic disease due to inconsistency in reporting, potential overlap in multiple studies reporting similar patients, and limited statistical analysis of the included studies. However, a few studies assessed the risk of worse
patient outcomes and considered demographic and clinical variables including comorbidities as predictors in the analysis.

Among all patients with COVID-19, those requiring treatment in an intensive care unit (ICU) were more likely to be older, male sex, and have an underlying comorbidity, specifically cerebrovascular disease (16.7% vs 1.0%).12 Similarly, patients who did not have clinical improvement or remission of symptoms within the first 10 days of hospitalization had higher incidence of preexisting cerebrovascular disease (8.2% vs 0%).11 Patients with COVID-19 and underlying cerebrovascular disease were also more likely to develop acute respiratory distress syndrome (11% vs 0%) in a cohort of 109 patients in Wuhan.18 Univariate analysis in a prospective cohort of 179 patients with COVID-19 pneumonia showed that preexisting cardiovascular or cerebrovascular disease was predictive of mortality (odds ratio = 11.059, 95% confidence interval = 4–30).29 We also observed a reported coincidence of Parkinson disease in COVID-19 similar to previously reported with SARS-CoV.15,31 This correlation has been previously explored in several publications.32

### Incidence of secondary neurologic disease after COVID-19

We found 10 publications reporting secondary neurologic events in patients diagnosed with COVID-19 (table 3). Four retrospective studies demonstrated a relationship between secondary neurologic events and treatment of COVID-19. One study demonstrated that 36% of 214 patients hospitalized for COVID-19 developed neurologic symptoms or secondary cerebral events.20 Another study demonstrated that 6% of 221 patients hospitalized for COVID-19 had an acute cerebrovascular event (ischemic stroke, cerebral thrombosis, and/or cerebral hemorrhage) while undergoing treatment.21 Hypoxic ischemic encephalopathy was reported in 20% of patients in another case series.24 A French study reported confusion in 65% patients and diffuse corticospinal signs in 67% patients during hospitalization. This study also reported dysexecutive syndrome in 33% of patients at discharge. Among 13 patients undergoing brain MRI in this study, 3 had acute/subacute ischemic strokes, 11 had bilateral frontotemporal hypoperfusion, and 8 had leptomeningeal enhancement with negative CSF RT-PCR.28 Older age, more severe illness, and underlying cardiovascular or cerebrovascular disease were risk factors for secondary cerebrovascular events.20,21 Further case reports have described various neurologic illnesses including acute necrotizing encephalopathy, ischemic strokes, seizures, intracranial hemorrhage, Guillain-Barre syndrome, and meningoencephalitis.22,33–37

### Discussion

These data suggest that patients with underlying neurologic impairment are vulnerable to more severe illness when infected with COVID-19. We saw a trend toward patients with preexisting cerebrovascular disease having higher risk of ICU admission as well as overall mortality. In addition, patients hospitalized with COVID-19 showed a 6%–36% incidence of neurologic events during the course of their illness.

---

**Table 1** Electronic database search strategy

<table>
<thead>
<tr>
<th>Aim</th>
<th>Search strategy with Boolean operators</th>
<th>Results*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence of neurologic comorbidity in patients hospitalized for COVID-19</td>
<td>(“covid-19”) AND (neuro* OR neurol manifestation))</td>
<td>190 156 8</td>
</tr>
<tr>
<td></td>
<td>(“covid-19”) AND (brain* OR brain infarct))</td>
<td>63 41 7</td>
</tr>
<tr>
<td></td>
<td>(“covid-19”) AND (stroke))</td>
<td>6 5 0</td>
</tr>
<tr>
<td></td>
<td>(“covid-19”) AND (seizure OR epilepsy)</td>
<td>2 3 0</td>
</tr>
<tr>
<td></td>
<td>(“covid-19”) AND (encephalitic OR encephalopathy))</td>
<td>15 3 2</td>
</tr>
<tr>
<td></td>
<td>(“covid-19”) AND (coma OR unconsciousness))</td>
<td>5 2 1</td>
</tr>
<tr>
<td></td>
<td>(“covid-19”) AND (cerebral edema OR “cereb*”))</td>
<td>22 7 0</td>
</tr>
<tr>
<td></td>
<td>(“covid-19”) AND (cranial hemorrhage OR intracranial hemorrhage OR subarachnoid hemorrhage)</td>
<td>1 2 0</td>
</tr>
<tr>
<td></td>
<td>(“covid-19”) AND (migraines OR “headache”))</td>
<td>28 20 18</td>
</tr>
<tr>
<td></td>
<td>(“covid-19”) AND (neuropathy OR neuromuscular OR myasthenia))</td>
<td>6 2 0</td>
</tr>
<tr>
<td></td>
<td>(“covid-19”) AND (dementia or neurocognitive disorder))</td>
<td>3 1 1</td>
</tr>
<tr>
<td>Total</td>
<td>341 242 37</td>
<td></td>
</tr>
</tbody>
</table>

* Search terms were applied with date filter of January 1, 2020, to April 12, 2020.
Table 2 Prevalence of preexisting neurologic diseases for patients hospitalized for COVID-19

<table>
<thead>
<tr>
<th>First author</th>
<th>Study design</th>
<th>Location</th>
<th>Sample</th>
<th>Diagnosis of COVID</th>
<th>Age (mean ± SD)</th>
<th>Male (%)</th>
<th>Neuro* comorbidity, n (%)</th>
<th>Description of neuro* comorbidity</th>
<th>Clinical notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guan et al.6</td>
<td>Retro</td>
<td>552 hospitals in 30 provinces</td>
<td>1,099</td>
<td>Confirmed with RT-PCR</td>
<td>44.2 ± 23.9</td>
<td>58</td>
<td>15 (1.4%)</td>
<td>Cerebrovascular disease</td>
<td>Comorbidity was more common in severe cases of COVID-19 (38.2% vs 22.5%)</td>
</tr>
<tr>
<td>Wu et al.10</td>
<td>Retro</td>
<td>Wuhan Jinyintan Hospital, in China</td>
<td>201</td>
<td>Confirmed with RT-PCR</td>
<td>51.5 ± 17.9</td>
<td>64</td>
<td>7 (3.5%)</td>
<td>Nervous system disease</td>
<td>Older patients with comorbidities of hypertension and diabetes more likely to develop ARDS</td>
</tr>
<tr>
<td>Mo et al.11</td>
<td>Retro</td>
<td>Zhongnan Hospital, Wuhan University</td>
<td>155</td>
<td>Confirmed with RT-PCR</td>
<td>53.5 ± 10.3</td>
<td>55</td>
<td>7 (4.5%)</td>
<td>Cerebrovascular disease</td>
<td>Patients with baseline cerebrovascular more likely to be in the refractory group</td>
</tr>
<tr>
<td>Cao et al.30</td>
<td>RCT</td>
<td>Jin Yin-Tan Hospital, Wuhan, China</td>
<td>199</td>
<td>Confirmed with RT-PCR</td>
<td>58.5 ± 11.2</td>
<td>60</td>
<td>13 (6.5%)</td>
<td>Cerebrovascular disease</td>
<td>Statistical analysis focused on intervention</td>
</tr>
<tr>
<td>Wang et al.14</td>
<td>Retro</td>
<td>First Affiliated Hospital of Zhengzhou University, Zhengzhou, China</td>
<td>18</td>
<td>Confirmed with RT-PCR</td>
<td>40.5 ± 7.5</td>
<td>56</td>
<td>2 (11.1%)</td>
<td>Stroke</td>
<td>2 patients with a history of stroke; time or severity of stroke not documented</td>
</tr>
<tr>
<td>Shi et al.13</td>
<td>Retro</td>
<td>Wuhan Jinyintan Hospital or Union Hospital of Tongji Medical College, Wuhan, China</td>
<td>81</td>
<td>Next-generation sequencing or RT-PCR</td>
<td>49.5 ± 11</td>
<td>52</td>
<td>6 (7%)</td>
<td>Cerebrovascular disease</td>
<td>Older age, male sex, and presence of comorbidity increase the risk of poor prognosis</td>
</tr>
<tr>
<td>Wang et al.15</td>
<td>Retro</td>
<td>Zhongnan Hospital of Wuhan University, Wuhan, China</td>
<td>138</td>
<td>Confirmed with RT-PCR</td>
<td>56.5 ± 20.2</td>
<td>54</td>
<td>7 (5.1%)</td>
<td>Cerebrovascular disease</td>
<td>Patients receiving ICU care were significantly older (66 vs 51) and had underlying cerebrovascular disease (16.7% vs 1.0% 1)</td>
</tr>
<tr>
<td>Deng and Peng15</td>
<td>Retro</td>
<td>Mainland China</td>
<td>26</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>4 (15.4%)</td>
<td>2 (7.7%)</td>
<td>Cerebral infarction and Parkinson disease</td>
</tr>
<tr>
<td>Wang et al.16</td>
<td>Retro</td>
<td>Wuhan, China</td>
<td>17</td>
<td>NR</td>
<td>71.5 ± 11.5</td>
<td>76</td>
<td>3 (18%)</td>
<td>2 (12%)</td>
<td>Cerebral infarction and Parkinson disease</td>
</tr>
<tr>
<td>Chen et al.17</td>
<td>Retro</td>
<td>Jinyintan Hospital in Wuhan, China</td>
<td>99</td>
<td>Confirmed with RT-PCR</td>
<td>55.5 ± 13.1</td>
<td>68</td>
<td>40 (40%)</td>
<td>Cardio-cerebrovascular disease and nervous system disease</td>
<td></td>
</tr>
<tr>
<td>Liu et al.18</td>
<td>Retro</td>
<td>Central Hospital, Wuhan</td>
<td>109</td>
<td>Confirmed with RT-PCR</td>
<td>55 ± 11</td>
<td>54</td>
<td>6 (5.5%)</td>
<td>Cerebrovascular disease</td>
<td>Older patients with severe COVID-19 more likely to develop neurologic complications</td>
</tr>
<tr>
<td>Chen et al.19</td>
<td>Retro</td>
<td>Shanghai Public Health Clinical Center (SPHCC), Shanghai, China</td>
<td>249</td>
<td>Confirmed with RT-PCR</td>
<td>51 ± 10</td>
<td>51</td>
<td>55 (21.7%)</td>
<td>Cardio-cerebrovascular disease</td>
<td>Older age and presence of any comorbidity associated with ICU stay</td>
</tr>
</tbody>
</table>

Continued
Table 2 Prevalence of preexisting neurologic diseases for patients hospitalized for COVID-19 (continued)

<table>
<thead>
<tr>
<th>First author</th>
<th>Study design</th>
<th>Location/Institution</th>
<th>Sample</th>
<th>Diagnosis of COVID</th>
<th>Age (mean ± SD)</th>
<th>Male (%)</th>
<th>Neuro* comorbidity</th>
<th>Clinical notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mao et al.20</td>
<td>Retro</td>
<td>Union Hospital of Huazhong University of Science and Technology, Wuhan, China</td>
<td>214</td>
<td>Confirmed with RT-PCR</td>
<td>52.8 ± 15</td>
<td>41</td>
<td>15 (7.0)</td>
<td>Cardiocerebrovascular disease was not different in severe and nonsevere cases</td>
</tr>
<tr>
<td>Li et al.21</td>
<td>Retro</td>
<td>Union Hospital, Wuhan, China</td>
<td>221</td>
<td>Confirmed with RT-PCR</td>
<td>53.3 ± 16</td>
<td>59</td>
<td>17 (7.7)</td>
<td>Cardiocerebrovascular disease. Older patients with severe COVID-19 more likely to develop neurologic complications</td>
</tr>
<tr>
<td>Filatov et al.22</td>
<td>Retro, Florida Atlantic University Hospital, Boca Rota, FL</td>
<td>1</td>
<td>NR</td>
<td>74</td>
<td>CR</td>
<td>1 (100)</td>
<td>Cardioembolic stroke and Parkinson disease</td>
<td>Case report of older male requiring ICU care with mechanical ventilation; developed encephalopathy</td>
</tr>
<tr>
<td>Onder et al.23</td>
<td>Retro</td>
<td>Italy</td>
<td>355</td>
<td>Confirmed with RT-PCR</td>
<td>NR</td>
<td>NR</td>
<td>24 (6.8) 34 (9.6)</td>
<td>Dementia and stroke</td>
</tr>
<tr>
<td>Chen et al.24</td>
<td>Retro</td>
<td>Tongji Hospital, Wuhan, China</td>
<td>274</td>
<td>Confirmed with PT-PCR</td>
<td>60 (11.5)</td>
<td>62</td>
<td>4 (1.5)</td>
<td>Cerebrovascular disease</td>
</tr>
<tr>
<td>Du et al.29</td>
<td>Prospec</td>
<td>Wuhan Pulmonary Hospital, Wuhan, China</td>
<td>179</td>
<td>Confirmed and probable cases</td>
<td>57.6 (13.7)</td>
<td>54%</td>
<td>29 (16.2)</td>
<td>Cardiocerebrovascular disease</td>
</tr>
<tr>
<td>Du et al.26</td>
<td>Retro</td>
<td>Hannan Hospital and Wuhan Union Hospital</td>
<td>85</td>
<td>Confirmed OR contact history</td>
<td>65.8 (14.2)</td>
<td>73</td>
<td>7 (8.2)</td>
<td>Cerebrovascular disease</td>
</tr>
<tr>
<td>Xu et al.25</td>
<td>Retro</td>
<td>Multiple hospitals in Zhejiang, China</td>
<td>62</td>
<td>Confirmed with RR-PCR</td>
<td>42 (14.7)</td>
<td>56</td>
<td>1 (2)</td>
<td>Cerebrovascular disease</td>
</tr>
<tr>
<td>Guo et al.27</td>
<td>Retro</td>
<td>Wuhan Union Hospital of Tongji Medical College, Huazhong University of Science and Technology</td>
<td>174</td>
<td>Confirmed with PT-PCR</td>
<td>58 (8.5)</td>
<td>44</td>
<td>13 (7.5)</td>
<td>Cerebrovascular disease</td>
</tr>
<tr>
<td>Heims et al.28</td>
<td>Retro</td>
<td>Strasbourg France</td>
<td>58</td>
<td>Confirmed with RT-PCR</td>
<td>63</td>
<td>NR</td>
<td>7 (12)</td>
<td>TIA, partial epilepsy, and mild cognitive impairment</td>
</tr>
<tr>
<td>Totals</td>
<td></td>
<td></td>
<td>4,014</td>
<td></td>
<td>55.68 (8.4)</td>
<td>57</td>
<td>322 (8.0%)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ARDS = acute respiratory distress syndrome; CR = case report; ICU = intensive care unit; NR = not reported; Prospec = prospective; Retro = retrospective; RCT = randomized control trial.
Whether the trend toward worse outcomes is related to vulnerability from neurologic disorders or the presence of other cardiovascular comorbidities leading to neurologic complications in these patients is difficult to discern without further data. The neurotropism of the coronavirus itself is being investigated as a possible mechanism behind the higher incidence of brainstem-mediated cardiopulmonary complications in patients who have more severe disease.\textsuperscript{38,39} Experimental data including autopsy samples of human brain tissue suggest a neuroinvasive potential of respiratory pathogens including coronaviruses in patients with and without preexisting neurologic disease.\textsuperscript{40–42} Published case series of other corona respiratory viruses like Middle East respiratory syndrome-related coronavirus (MERS-CoV) and severe acute respiratory syndrome-related coronavirus (SARS-CoV) in prior years have listed similar neurologic complications including intracranial hemorrhage, ischemic stroke, polyneuropathy, Bickerstaff encephalitis, and Guillain-Barré syndrome.\textsuperscript{43}

Further data on the vulnerability of patients with neurologic illness may be impactful in targeting this population for proactive viral screening. Risk stratification scores that identify patients at high risk of deterioration or that qualify patients for empiric therapies like hydroxychloroquine also need to reconsider adding patients with cerebrovascular disease.\textsuperscript{8}

The burden of neurologic events occurring in hospitalized patients demonstrates the need for appropriate infrastructure to facilitate neurologic assessments in this population that may be deterred by the cumbersome nature of protection required for clinical assessments. This infrastructure may include a robust supply of PPE for neurologists to assess patients, telemedicine alternatives for remote assessment of bedside examination, and protocols for transporting these patients for neuroimaging including emergent evaluation for cerebrovascular disease.

This scoping review has several limitations. Our analyses are limited by small sample sizes, even smaller incidences of neurologic comorbidities, lack of long-term follow-up, and the possibility of overlap in populations described in reviewed articles potentially biasing the results. The studies included in this scoping review also have inherent bias based on the study designs. The retrospective nature of most of the included studies potentially presents selection and presentation bias. Retrospective studies are subject to misclassification bias with limited ability to control for all potential confounders. In addition, retrospective studies require large sample sizes to generate statistical power to determine different in-study end points. We did not specifically perform a risk of bias assessment in this scoping review, but instead choose to focus on the overall prevalence. Lack of neurologic history reported in medical records by an overstretched health care system, lack of exhaustive reporting of neurologic comorbidities in acutely reported publications, and challenges of neurologic assessments...
or neuroimaging in patients with COVID-19 may have contributed to the lower reported incidence of neurologic comorbidities or secondary neurologic events in hospitalized patients. Two meta-analyses reporting comorbidities in COVID-19 and MERS-CoV failed to report neurologic comorbidities, highlighting challenges of collecting such data.\textsuperscript{7,44} We were unable to perform meta-analysis or predict worse outcomes based on comorbidity status.

### Conclusions

The culmination of studies indicates a daunting clinical relationship between COVID-19 and secondary neurologic complications and needs a concerted effort by neurologists to reorganize consultative practices to serve the neurologic needs of patients during this pandemic. More sensitive data extraction measures and comprehensive clinical documentation are required to better understand the prevalence of neurologic comorbidities and preexisting neurologic disorders in patients with COVID-19.

**Study funding**

No targeted funding reported.

**Disclosure**

The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

**Publication history**

Received by Neurology March 25, 2020. Accepted in final form April 22, 2020.
Appendix Authors

<table>
<thead>
<tr>
<th>Author</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collin Herman, MD</td>
<td>Department of Neurology, Wake Forest Baptist Medical Center, Winston Salem, NC</td>
<td>Drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td>Kirby P. Mayer, DPT, PhD</td>
<td>Department of Physical Therapy, University of Kentucky College of Health Sciences, Lexington, KY</td>
<td>Major role in the acquisition of data; performed statistical review of results; interpreted the data; and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Aarti Sarwal, MD</td>
<td>Department of Neurology, Wake Forest Baptist Medical Center, Winston Salem, NC</td>
<td>Designed and conceptualized the study; major role in the acquisition of data; interpreted the data; and revised the manuscript for intellectual content</td>
</tr>
</tbody>
</table>

References

Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19
Collin Herman, Kirby Mayer and Aarti Sarwal
Neurology 2020;95;77-84 Published Online before print April 28, 2020
DOI 10.1212/WNL.0000000000009673

This information is current as of April 28, 2020

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/95/2/77.full

References
This article cites 34 articles, 7 of which you can access for free at:
http://n.neurology.org/content/95/2/77.full#ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
http://n.neurology.org/content/95/2/77.full##otherarticles

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise

Neurology ® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2020 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.